SLGL
Sol-Gel Technologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$60.00
−7.03%Sep 17, 2026, 12:30 UTC
Sol-Gel Technologies announced that the last patient completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Source:Aug 20, 2026, 12:30 UTC
Sol-Gel Technologies reported its financial results for the second quarter ended June 30, 2026.
Source: